See more : CITIC Securities Company Limited (6030.HK) Income Statement Analysis – Financial Results
Complete financial analysis of NeoGenomics, Inc. (NEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeoGenomics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- MLP Group S.A. (MLG.WA) Income Statement Analysis – Financial Results
- HH&L Acquisition Co. (HHLA) Income Statement Analysis – Financial Results
- Armor Minerals Inc. (RCZRF) Income Statement Analysis – Financial Results
- PT Satria Antaran Prima Tbk (SAPX.JK) Income Statement Analysis – Financial Results
- Compass Diversified (CODI-PA) Income Statement Analysis – Financial Results
NeoGenomics, Inc. (NEO)
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 591.64M | 509.73M | 484.33M | 444.45M | 408.83M | 276.74M | 258.61M | 244.08M | 99.80M | 87.07M | 66.47M | 59.87M | 43.48M | 34.37M | 29.47M | 20.02M | 11.50M | 6.48M | 1.89M | 558.07K | 369.97K | 93.49K | 1.00K | 252.40K |
| Cost of Revenue | 347.04M | 321.83M | 297.27M | 258.56M | 211.99M | 149.48M | 138.30M | 133.70M | 56.05M | 46.36M | 34.73M | 33.03M | 24.06M | 18.59M | 14.25M | 9.35M | 5.52M | 2.76M | 1.19M | 576.87K | 481.59K | 189.96K | 0.00 | 74.29K |
| Gross Profit | 244.60M | 187.90M | 187.06M | 185.89M | 196.84M | 127.27M | 120.32M | 110.38M | 43.76M | 40.71M | 31.74M | 26.84M | 19.43M | 15.78M | 15.21M | 10.66M | 5.98M | 3.72M | 696.92K | -18.79K | -111.62K | -96.47K | 1.00K | 178.11K |
| Gross Profit Ratio | 41.34% | 36.86% | 38.62% | 41.83% | 48.15% | 45.99% | 46.52% | 45.22% | 43.84% | 46.76% | 47.75% | 44.83% | 44.68% | 45.92% | 51.63% | 53.27% | 52.00% | 57.39% | 36.97% | -3.37% | -30.17% | -103.18% | 100.00% | 70.57% |
| Research & Development | 27.31M | 30.33M | 21.87M | 8.23M | 8.49M | 3.00M | 3.64M | 4.65M | 4.20M | 2.69M | 2.44M | 2.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.41K | 0.00 | 0.00 |
| General & Administrative | 243.10M | 243.36M | 221.35M | 143.79M | 127.99M | 84.82M | 88.76M | 75.78M | 33.63M | 23.81M | 17.40M | 15.84M | 12.87M | 11.27M | 10.06M | 0.00 | 0.00 | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 0.00 | 0.00 |
| Selling & Marketing | 70.84M | 67.32M | 62.59M | 47.86M | 47.35M | 29.40M | 24.54M | 23.91M | 11.56M | 12.00M | 8.73M | 7.50M | 6.96M | 7.48M | 6.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 313.04M | 310.68M | 283.94M | 191.66M | 175.34M | 114.22M | 113.30M | 99.69M | 45.19M | 35.81M | 26.12M | 23.34M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 8.08M | 1.12M |
| Other Expenses | 11.99M | -213.00K | -499.00K | 11.86M | -4.63M | 14.00K | -1.32M | 3.46M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.40K |
| Operating Expenses | 352.34M | 341.00M | 305.81M | 199.89M | 183.83M | 117.23M | 116.93M | 104.34M | 49.39M | 38.50M | 28.56M | 25.63M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 487.21K | 8.08M | 1.15M |
| Cost & Expenses | 699.38M | 662.84M | 603.08M | 458.44M | 395.82M | 266.70M | 255.23M | 238.05M | 105.44M | 84.85M | 63.29M | 58.66M | 43.89M | 37.33M | 31.20M | 20.90M | 14.65M | 6.34M | 2.69M | 1.29M | 864.30K | 677.16K | 8.08M | 1.22M |
| Interest Income | 16.90M | 6.08M | 3.14M | 3.06M | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.91M | 1.51M | 5.08M | 7.02M | 3.71M | 6.23M | 5.54M | 10.00M | 854.00K | 929.00K | 989.00K | 1.15M | 768.00K | 710.00K | 532.39K | 308.52K | 0.00 | 325.63K | 196.80K | 0.00 | 41.43K | 207.31K | 0.00 | 0.00 |
| Depreciation & Amortization | 72.58M | 79.21M | 62.07M | 41.89M | 35.91M | 21.73M | 22.59M | 23.21M | 7.14M | 5.64M | 4.41M | 3.82M | 2.09M | 1.78M | 1.18M | 740.56K | 506.36K | 306.59K | 181.07K | 104.26K | 48.04K | -207.31K | 245.67K | 26.40K |
| EBITDA | -17.61M | -78.63M | 52.08M | 34.85M | 43.26M | 31.79M | 26.55M | 29.25M | 3.51M | 7.86M | 7.59M | 5.03M | 1.68M | -812.00K | -526.31K | -143.43K | -2.63M | 446.58K | -619.30K | -625.30K | -446.30K | -583.67K | -7.83M | -944.53K |
| EBITDA Ratio | -2.98% | -16.46% | 8.95% | 7.56% | 9.45% | 11.49% | 9.53% | 11.98% | 3.51% | 2.55% | 4.78% | 8.40% | 3.85% | -4.52% | -1.90% | -0.77% | -23.11% | 6.03% | -32.85% | -112.05% | -120.63% | -624.31% | -783,229.50% | -374.47% |
| Operating Income | -107.74M | -153.11M | -9.99M | -2.13M | 8.38M | 10.04M | 3.38M | 2.57M | -5.64M | 2.22M | 3.17M | 1.21M | -409.00K | -2.96M | -1.73M | -883.99K | -3.14M | 139.99K | -800.36K | -729.56K | -494.33K | -583.67K | -8.08M | -970.93K |
| Operating Income Ratio | -18.21% | -30.04% | -2.06% | -0.48% | 2.05% | 3.63% | 1.31% | 1.05% | -5.65% | 2.55% | 4.78% | 2.02% | -0.94% | -8.62% | -5.86% | -4.42% | -27.30% | 2.16% | -42.45% | -130.73% | -133.61% | -624.31% | -807,796.60% | -384.67% |
| Total Other Income/Expenses | 10.64M | -1.72M | 103.68M | -64.00K | -9.36M | -6.22M | -5.55M | -10.00M | 1.15M | -929.00K | -989.00K | -1.15M | -768.00K | -340.00K | -515.30K | -498.60K | -239.20K | -139.99K | -196.80K | -89.42K | 0.00 | 0.00 | 0.00 | 646.00 |
| Income Before Tax | -97.10M | -159.34M | -15.08M | -14.06M | 3.65M | 3.82M | -3.48M | -7.42M | -4.49M | 1.29M | 2.19M | 65.00K | -2.70K | -2.59M | -1.71M | -1.07M | -3.12M | 139.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -970.28K |
| Income Before Tax Ratio | -16.41% | -31.26% | -3.11% | -3.16% | 0.89% | 1.38% | -1.35% | -3.04% | -4.50% | 1.48% | 3.29% | 0.11% | -0.01% | -7.54% | -5.80% | -5.37% | -27.09% | 2.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -384.42% |
| Income Tax Expense | -9.13M | -15.09M | -6.73M | -18.23M | -4.36M | 1.18M | -2.64M | -1.70M | -1.95M | 157.00K | 152.00K | 1.15M | 768.00K | -740.00K | -34.18K | 180.15K | 214.94K | -111.94K | 196.80K | 89.42K | 41.43K | 214.16K | 0.00 | -1.29K |
| Net Income | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -846.00K | -5.72M | -2.54M | 1.13M | 2.03M | 65.00K | -1.18M | -3.30M | -2.24M | -1.38M | -3.38M | -129.66K | -997.16K | -818.99K | -535.76K | -590.52K | -8.08M | -970.28K |
| Net Income Ratio | -14.87% | -28.30% | -1.72% | 0.94% | 1.96% | 0.95% | -0.33% | -2.34% | -2.54% | 1.30% | 3.06% | 0.11% | -2.71% | -9.61% | -7.61% | -6.91% | -29.38% | -2.00% | -52.89% | -146.75% | -144.81% | -631.64% | -807,796.60% | -384.42% |
| EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| EPS Diluted | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| Weighted Avg Shares Out | 125.50M | 124.22M | 119.96M | 108.58M | 100.47M | 91.57M | 78.16M | 77.04M | 60.53M | 53.48M | 48.26M | 45.03M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
| Weighted Avg Shares Out (Dil) | 125.50M | 124.22M | 119.96M | 111.79M | 103.62M | 91.57M | 79.43M | 77.54M | 60.53M | 56.02M | 52.78M | 48.72M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know
NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
Source: https://incomestatements.info
Category: Stock Reports